(Charlottetown, PE, March 15, 2018) Neurodyn Cognition Inc. (‘Neurodyn’ or the ‘Company’) today announced that its’ collaborators from The Center for Human Drug Research (Leiden,NL) will present a poster at the 2018 Annual Meeting of the American Society for Clinical Pharmacology & Therapeutics (ASCPT) taking place from March 21 to 24, 2018, in Orlando, Florida. The poster will feature pharmacokinetic (PK) and pharmacodynamic (PD) outcomes of a MAD study of its’ Alzheimer disease drug candidate Memogain, with a focus on the improved brain function determined by quantitative EEG. As a prodrug of an approved treatment for Alzheimer’s disease, Memogain has been developed to exhibit increased efficacy, and a reduced side effect profile
“We are very excited about the data we are presenting at ASCPT and remain committed to developing safer and more effective treatments for patients,” says Kay.
“Our study has demonstrated Memogain to be safe with few side effects and showed improvements in sustained attention and working memory in elderly individuals.”
About Neurodyn Cognition
Neurodyn Cognition Inc. ( http://www.neurodyncognition.ca ) is a private Canadian biotech company developing Memogain, a patented prodrug of an approved treatment for Alzheimer’s disease, galantamine (Reminyl®). Memogain’s intranasal administration achieves higher dose levels, with significantly greater brain bioavailability, while avoiding the compliance impairing gastro-intestinal adverse effects of existing symptomatic treatments. In addition to improved cognition the increased brain concentrations enhances the drugs unique and safe mechanism of sensitization of neuronal nicotinic acetylcholine receptors, most notably the alpha-7 subtype, which could result in the potential for disease modifying neuroprotective effects.
About The American Society for Clinical Pharmacology & Therapeutics
The American Society for Clinical Pharmacology & Therapeutics ( https://www.ascpt.org ) , founded in 1900, is the largest scientific and professional organization serving the disciplines of clinical pharmacology and translational medicine.
For more information, please contact:
Mr. Kenneth Cawkell, Chief Executive Officer
firstname.lastname@example.org | 1.604.619.0990
Dr. Denis Kay, Chief Scientific Officer
email@example.com | 1.902.314.0776